Search results
Researchers make crucial discovery about drought-resistant plants: 'A grand challenge for...
The Cool Down via Yahoo News· 3 days agoOther scientists have used the same genetic modification technology, known as CRISPR, to create...
Tardigrade gene edit a first step towards exposing their secrets
Cosmos· 5 days agoTiny, tubby and seemingly indestructible tardigrades might become a little less mysterious to...
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
Zacks· 4 days agoFree Report) reported new positive data from the phase I/II/III RUBY study of its lead candidate, reni-cel, in 18 patients with sickle cell disease (SCD) and the phase I/II EdiTHAL study of ...
Scientists Want to Resurrect the Woolly Mammoth, but Is It a Good Idea?
CCM· 1 day agoAfter making considerable progress in the field of genetics, scientists are looking at bringing...
Two Big Trends from InfoComm 2024
AV Network via Yahoo News· 7 days agoAV Technology's Cindy Davis cites that artificial intelligence (AI) and industry partnerships are poised to reshape the AV/IT industry in ways we can't...
Health care's biggest wild card
Axios· 7 days agoWhen I've asked CEOs what they see as the wild card that will shape health care's future, almost all of them have mentioned emerging technology,...
YolTech and KACTUS Join Forces to Propel Innovative DNA editing system in Greater China
The Pilot News· 2 days agoYolTech, a clinical-stage biopharmaceutical company specializing in mRNA-LNP delivery for in vivo gene editing therapies, has partnered with KACTUS, a leading developer serving the biopharmaceutical ...
Novel gene-editing therapy continues to show positive results in sickle cell patients
Medical Xpress· 6 days agoConducted as part of the multicenter RUBY Trial, researchers shared data on the safety and...
Oppenheimer Reiterates Market Perform Rating for Editas Medicine (NASDAQ:EDIT)
ETF DAILY NEWS· 1 day agoEditas Medicine (NASDAQ:EDIT – Get Free Report)‘s stock had its “market perform” rating restated by research analysts at Oppenheimer in a report issued on Tuesday, Benzinga reports. Oppenheimer ...
3 Growth Stocks You Can Buy Right Now Without Any Hesitation | The Motley Fool
The Motley Fool· 6 days agoThree Motley Fool contributors believe they've identified good picks -- and they're all big biotech...
